Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 02
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Hims & Hers Health Inc
HIMS
NYSE
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$29.34
0.0436
0.15%
Últ. Act.: Oct 1, 7:57 PM
$29.34
0.0436
0.15%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Hims & Hers Health Financials
Hims & Hers Health (HIMS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst
HIMS stock edges lower after mixed Q2 results. Needham analyst maintains Buy rating, raises PT to $42. Company's revenue up 38.2% YoY.
Priya Nigam
Hims & Hers Shares Drop After Mixed Q2 Earnings — Details
Hims & Hers posted Q2 results - here are the details you need to know.
Erica Kollmann
PRO
Hims & Hers Health Sees Q3 Sales $880.000M-$900.000M vs $793.071M Est
Hims & Hers Health (NYSE:HIMS) sees Q3 sales of $880.000 million-$900.000 million vs $793.071 million analyst estimate.
Benzinga Newsdesk
PRO
Hims & Hers Health Raises FY2026 Sales Guidance from $2.800B-$3.000B to $3.100B-$3.300B vs $2.928B Est
Hims & Hers Health (NYSE:HIMS) raises FY2026 sales outlook from $2.800 billion-$3.000 billion to $3.100 billion-$3.300 billion vs $2.928 billion estimate.
Benzinga Newsdesk
PRO
Hims & Hers Health Q2 EPS $(0.37) Misses $(0.03) Estimate, Sales $753.214M Beat $699.889M Estimate
Hims & Hers Health (NYSE:HIMS) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.03) by 1133.33 percent. This is a 317.65 percent decrease over earnings of $0.17 per
Benzinga Newsdesk
Hims & Hers Health Likely To Report Q2 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
HIMS to release Q2 earnings on Aug. 10, expected to report a loss of 5 cents/share. FDA panel voted to add BPC-157 to compounding list. Stock rose 6.5% on Friday.
Avi Kapoor
